Multiple Sclerosis Discovery Forum

Inspiring Connections

Most Viewed Papers

Dalfampridine improves walking speed, walking endurance, and community participation in veterans with multiple sclerosis: a longitudinal cohort study.
International consensus diagnostic criteria for neuromyelitis optica spectrum disorders.
Fingolimod increases brain-derived neurotrophic factor levels and ameliorates amyloid β-induced memory impairment.
Intermittent Atrioventricular Block following Fingolimod Initiation.
A manual of diseases of the nervous system
Efficacy and safety of subcutaneous interferon-β-1a in patients with a first demyelinating event and early multiple sclerosis.
Significance of Virchow-Robin Spaces in Patients Newly Diagnosed with Multiple Sclerosis: A Case-Control Study in an Arab Population.
Trial watch: Chemotherapy with immunogenic cell death inducers.
Do neutralising antibodies against exogenous interferon-beta inhibit endogenous signalling pathways?
T-cell response against varicella-zoster virus in fingolimod-treated MS patients.
[Unified assessment of adverse events of multiple sclerosis disease modifying drugs.]
Regulatory effects of fisetin on microglial activation.
Is natalizumab overshooting its rebound?
The refinement of genetic predictors of multiple sclerosis.
B cells populating the multiple sclerosis brain mature in the draining cervical lymph nodes.
Renin-angiotensin system gene polymorphisms as risk factors for multiple sclerosis.
Cortical Perfusion Alteration in Normal-Appearing Gray Matter Is Most Sensitive to Disease Progression in Relapsing-Remitting Multiple Sclerosis.
The nocebo effect: A clinicians guide.
Reversible cerebral vasoconstriction syndrome associated with fingolimod treatment in relapsing-remitting multiple sclerosis three months after childbirth.
Wnt Signaling in the Pathogenesis of Multiple Sclerosis-Associated Chronic Pain.
Review of MR elastography applications and recent developments.
Immune parameters of patients treated with laquinimod, a novel oral therapy for the treatment of multiple sclerosis: results from a double-blind placebo-controlled study.
Simvastatin: two decades in a circle.
Multiple sclerosis and bipolar disorders: The burden of comorbidity and its consequences on quality of life.
Kappa free light chains: diagnostic and prognostic relevance in MS and CIS.

Pages